Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3 ...

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect MiNK Therapeutics to post earnings of ($0.

MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T ...

Get Our Latest Report on INKT MiNK Therapeutics Stock Down 0.6 % NASDAQ:INKT opened at $9.26 on Wednesday. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $19.00. The company ...

The funding will also support the expansion of the company’s solid tumor programs and strengthen its iNKT cell therapy pipeline, positioning Arovella to achieve significant milestones ...

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Dylan Berman Why Byrna Technologies ...

“These latest data demonstrate the remarkable potential of combining BOT/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors,” said Dr ...